PCSK9: a convertase that coordinates LDL catabolism
Howard Hughes Medical Institute · Southwestern Medical Center · +1 more institution
Abstract
The identification and characterization of proprotein convertase subtilisin-like/kexin type 9 (PCSK9) have provided new insights into LDL metabolism and the causal role of LDL in coronary heart disease (CHD). PCSK9 is a secreted protease that mediates degradation of the LDL receptor by interacting with the extracellular domain and targeting the receptor for degradation. Individuals with loss-of-function mutations in PCSK9 have reduced plasma levels of LDL cholesterol and are protected from CHD; these observations have validated PCSK9 as a therapeutic target and suggested new approaches for the treatment and prevention of CHD. The identification and characterization of proprotein convertase…
Citation impact
- FWCI
- 21.18
- Percentile
- 100%
- References
- 54
Authors
3- JDJay D. HortonCorresponding
Howard Hughes Medical Institute, Southwestern Medical Center, The University of Texas Southwestern Medical Center
- JCJonathan C. Cohen
The University of Texas Southwestern Medical Center
- HHHelen H. HobbsCorresponding
Howard Hughes Medical Institute, Southwestern Medical Center, The University of Texas Southwestern Medical Center
Topics & keywords
- PCSK9
- Proprotein convertase
- Kexin
- LDL receptor
- Subtilisin
- Catabolism
- Chemistry
- Cholesterol
- Good health and well-being